Biotechnology manufacturing opportunities in India
Biotechnology manufacturing is certainly one of the most interesting business concepts that are on the rise in today’s industrial scene in India. While many industries have already seen the death of first-mover advantage, the biotech manufacturing industry in India stands at a real tipping point, with its landscape reshaped by demand coming from its domestic market, supply chains in flux, and an institutional policy push that is providing and de-risking new players in unprecedented ways. Today, for the first time, well-informed entrepreneurs, investors in MSMEs, and future-minded startup founders can have easy access to what was once the exclusive domain of large pharmaceutical groups and research institutes.
The biotech industry has experienced a structural shift of the industry in the last ten years. The biologics industry including recombinant proteins, monoclonal antibodies, vaccines, biosimilars, diagnostic enzymes, and industrial fermentation products has become the driver of growth in life sciences in place of small molecule chemistry. India has a long history of pharmaceutical manufacturing, a large pool of highly skilled STEM graduates, and a strong cost advantage. These strengths equip the country well to benefit from contract manufacturing in regulated markets and to build its own branded export base. Imagine India’s biotechnology industry is worth more than USD 80 billion with the potential of reaching USD 300 billion this decade, which makes it one of the fastest growing industries in the country.
Why Biotechnology Manufacturing Is a Smart Industrial Bet
The demand for biotech manufacturing in India is based on a minimum of three independent pillars and each of these would warrant serious investment attention in its own right. The first is the domestic consumption, where India is seeing unprecedented volume for biologics, diagnostics and nutraceutical-grade fermentation products driven by its disease burden, ageing population, and increasing health insurance coverage under Ayushman Bharat. Domestic demand of biosimilars alone is projected to be worth several billion dollars as branded biologics are about to hit patent cliffs across the world and Indian generic manufacturers are moving quickly to meet the demand.(Biotechnology manufacturing opportunities in India)
The second strand involves contract manufacturing, which is focused on exports. Global innovator companies, especially in the U.S. and Europe, are keen to diversify away from geography dependency in their supply chains, covering both API and biologic products. India’s regulatory credibility has been established for decades with the USFDA, EMA and WHO GMP approvals and it makes Indian a natural secondary centre. When a new player wants to start a proper fermentation or cell culture unit, or facility, in the right location and to the right standard, and obtain the right certifications, contract manufacturing agreements with foreign partners are no longer a dream; they are a business reality.
The third pillar is industrial biotechnology: microbial and enzymatic processes in the food industry, agrochemicals, textile processing and specialty chemicals. This segment is far less sexy than pharmaceuticals, but probably more attainable for first generation entrepreneurs. Enzyme and bio-pesticide companies, probiotic supplement companies, and fermentation-based specialty ingredient companies have consistently had better margins and lower regulatory entry barriers than pharmaceutical biologics.
Get Detailed Insights from This Book: Handbook on Small & Medium Scale Industries (Biotechnology Products)
Government Policies and Incentives Supporting Biotech Manufacturing
The policy landscape is, to put it in no uncertain terms, the most pro-business one it’s ever had for biotech manufacturing. The Department of Biotechnology (DBT) under the Ministry of Science and Technology has several grant, soft-loan and co-investment schemes specifically for the early-stage biotech manufacturers. The Bio NEST (Bio incubators Nurturing Entrepreneurship for Scaling Technologies) programme supports bio incubation facilities in academic institutions, thereby relieving startups from the financial strain of the construction of their own GMP facilities from the beginning.
The Production Linked Incentive (PLI) Scheme for Pharmaceuticals, administered by the Department of Pharmaceuticals, covers advanced chemical entities and biopharmaceuticals. Under this scheme, manufacturers can receive incentives of up to 10–20% of the additional sales generated over a period of time compared to a base year.
This scheme can act as a form of subsidy for a considerable proportion of the revenue risk in the early commercialization stage of the manufacturing process, as a manufacturer scales from a pilot facility to commercial capacity.
The MSME Ministry’s CGTMSE scheme offers collateral-free loan guarantees for loans of up to ₹2 crore for eligible manufacturing startups, alleviating the pressure on the promoters who do not have any assets for collateral. Section 80-IAC of the Income Tax Act complements this by granting DPIIT-recognized startups three years of tax-free profits. This provides a major financial benefit to capital-intensive manufacturing companies, which typically become profitable only in their third or fourth year.
Another important point to note is the public sector institution DBT’s Biotechnology Industry Research Assistance Council (BIRAC) which has allocated more than ₹2000 crore for funding support to biotech startups and SMEs. BIRAC’s SBIRI (Small Business Innovation Research Initiative) and BIPP (Biotechnology Ignition Grant and Entrepreneurship Development Programmer) essentially act as risk-sharing mechanisms for new biotech manufacturers, and savvy entrepreneurs actively use them to raise capital and develop innovations.(Biotechnology manufacturing opportunities in India)
Business Ideas for Startups in Biotechnology Manufacturing
1. Biosimilar API Manufacturing
The opportunity is clearly the largest commercial one in India today in the biotech manufacturing segment – the biosimilar opportunity. Globally, the need for high-quality and cost-competitive biosimilar APIs is growing as blockbuster biologics, such as the widely used anti-TNF drugs, insulin analogues and erythropoietin drugs, come off patents in key regulated markets. A cell culture or microbial fermentation facility owner that complies with WHO GMP or USFDA standards can provide services to formulation businesses within the country, directly undertake export orders, and handle toll manufacturing deals with foreign innovators. The investment range for a commercially viable biosimilar API plant is from ₹10 crore to ₹50 crore depending on the product category and size, however, revenue trajectory with an Anchor Customer – Contract Manufacturing Organization (CMO) can enable payback period in four to six years even at 50% product utilization.
2. Industrial Enzyme Manufacturing
Industrial enzymes is one of the most overlooked verticals for MSME investors in the biotech industry. The food processing, textile, animal feed, detergent and paper industries use huge quantities of enzymes like proteases, amylases, lipases, cellulases and phytases.
Increased demand for enzymes for the global industrial market has been gradual, in part due to the rising interest in ‘clean label’ technologies used in the food industry, and in part due to the growing pressure on industry to move away from harsh chemical processing methods, towards enzymatic alternatives, as a result of sustainability requirements.
The cost of setting up an enzyme production unit in India in the fermentation technology is in the range of ₹3 crore to ₹8 crore with the opportunity of offering specialty or application-specific enzyme blends instead of commodity grades.
This area offers export-oriented opportunities, and entrepreneurs who have access to industrial microbiology skills and strong cold-chain logistics can best exploit them. (Biotechnology manufacturing opportunities in India)
3. Bio-Pesticide and Bio-Fertiliser Manufacturing
India’s agriculture transition is not a cyclical one but a basic structural one towards chemical farming. The demand for microbial bio-pesticides and biofertilisers is on the rise due to a combination of factors, including centuries of conventional soil degradation, closer limits on the use of MRL (maximum residue limit) on exported crops, and farmer interest in alternatives that do not require as much input as conventional options.Decades-long conventional soil degradation, increased restrictions on the use of MRL (maximum residue limit) for export crops, and farmer desires for lower input cost alternatives all are driving higher demand for microbial bio-pesticides and biofertilisers that is exceeding supply capacity.
Biofertilisers such as Trichoderma-based fungicides, Beauveria bassiana-based insecticides, Azospirillum and Rhizobium biofertilisers, and Pseudomonas-based biocontrol products have now become well established. Organized agrochemical distributors and state agriculture departments increasingly procure and supply these products.
A bio-pesticide manufacturing unit with a capacity of 100–500 tonnes per year (formulated product) is a moderately capital-intensive venture. It typically requires an investment of around ₹1.5 crore to ₹4 crore. It can generate good returns if the promoter builds strong field networks and trains farmers while scaling up operations.
Get Detailed Project Report (DPR): Industrial Biotechnology, Enzymes & Biofertilizers
4. Diagnostic Reagent and Rapid Test Kit Manufacturing
COVID-19 radically shifted the measurement of India’s diagnostic manufacturing plans. The provision of diagnostic raw materials and assemblies was a predominantly import-reliant component, and Chinese countries provided almost all of the supplies, hence it was an immediate industrial priority.
Today, government procurement programmes, Ayushman Bharat diagnostic incentives and the vastly growing private diagnostic laboratory network all support the demand for locally produced diagnostic kits that is far beyond the pandemic emergency buying spree.
The development of new, innovative diagnostic tests can help close this significant gap. This is especially important in the TB, dengue, typhoid, HBsAg, and HIV diagnostic markets.
The manufacturing of diagnostic reagents typically requires operating a controlled-environment facility (Class 10,000 clean room or better), maintaining proper cold-chain logistics, and obtaining CDSCO registration. A well-prepared promoter with a focused product portfolio can achieve this process without major difficulty, as it is not overly complex.(Biotechnology manufacturing opportunities in India)
5. Probiotic and Nutraceutical Contract Manufacturing
The nutraceutical industry is one of the fastest-growing manufacturing verticals in India. However, domestic manufacturing capacity is still much lower than both domestic and export demand. This gap is especially visible in probiotics and fermentation-derived ingredients.
Dietary supplement brands, functional food companies, infant formula manufacturers, and institutional healthcare procurement agencies use these products.
These include lactic acid bacteria, Bifidobacterium strains, and specialty postbiotics.
A key advantage for contract manufacturers in this segment is access to branded supplement companies. They do not need to build a consumer brand themselves. They also benefit from custom strain selection, stability testing, and private-label packaging.
Setting up a commercially viable probiotic manufacturing unit requires significant investment. With a spray-drying facility, the cost typically ranges from ₹4 crore to ₹10 crore. Once GMP certification is obtained, the business model becomes highly scalable.
Import–Export Opportunity Analysis
The trade profile of India’s biotechnology industry highlights the need to develop a functional MSME manufacturing ecosystem, which stakeholders have not fully tapped yet. However, India still imports thousands of crores worth of biologic APIs, raw materials for diagnostics, specialty enzymes, cell culture media every year, on which domestic production could increasingly replace imports with a concerted policy and entrepreneurial effort. India’s exports of specialty biotechnology products are small compared to the potential exports that are being indicated by the country’s manufacturing and talent base, according to data compiled by the Chemicals and Fertilizers Export Promotion Council (Chemexcil).
Identify high-growth industries before others do
The opportunity is especially strong on the export front, particularly for biosimilars for regulated markets over the Southeast Asia, Africa and Latin American, where public health systems are often unable to afford branded biologics, and India manufacturers who hold WHO GMP certification can make a big price impact. Developing new, innovative diagnostic tests helps close this significant gap. This is especially important for diagnosing TB, dengue, typhoid, HBsAg, and HIV. The government’s emphasis on bilateral trade agreements and a growing range of products in the market access portfolio for Indian pharma and biotech companies is a good indicator of the investment climate for manufacturers to make now.
Indian MSME Success Stories in Biotech Manufacturing
Biocon Biologics — From MSME Origins to Global Biosimilar Leader
The path of Biocon, under the leadership of its founder Kiran Mazumdar-Shaw, is one of the most studied in Indian biotech. The company began as an enzyme manufacturer. It used fermentation technology to produce papain and isinglass for the brewing industry. Later, it became the largest producer of statin APIs. Eventually, it grew into the world’s largest manufacturer of biosimilars.
This approach to decision logic focused more on capability building than short-term margin optimization. It aimed to invest in a proprietary fermentation platform. At the same time, it continued exploring USFDA and EMA approval routes before they became commercially necessary.
It also involved entering strategic partnerships (with Mylan and later Vitara’s). These partnerships helped gain access to global distribution networks while still maintaining manufacturing control. For new biotech entrepreneurs, the takeaway is that building a manufacturing platform with quality and regulatory integrity can create a sustainable competitive moat. (Biotechnology manufacturing opportunities in India
Serum Institute of India — Scale, Cost Discipline, and Mission Alignment
Cyrus Poonawalla’s Serum Institute is a strong case study in manufacturing scale, cost discipline, and a realistic understanding of the addressable market. It shows how these factors can build a business that is both commercially powerful and socially important.
Serum became the world’s largest vaccine manufacturer. It did not rely mainly on advanced research and development. Instead, it focused on efficient manufacturing.
The company built strength through excellence in production. It also invested in backward integration, including the manufacture of cell culture media. In addition, it produces essential inputs like glass vials. Serum committed early and continuously to WHO pre-qualification, which opened up global procurement streams to them. For MSME entrepreneurs in biotech manufacturing, the key learning is that quality management systems and regulatory approval portfolios are strategic assets.
They are as important as production assets and are often more important in determining price and customer acquisition cost.
Bharat Biotech – Innovation-led Manufacturing in a Domestic Sphere
Krishna Ella’s Bharat Biotech offers a different story. It is an Indian company that heavily invested in proprietary technology platforms. They carried this out in a market that preferred buying or licensing technology instead of building it in-house.
However, several success stories changed that perception. The biggest example is Covaxin during the recent pandemic. It showed that Indian biotech can innovate and scale novel biologics. It can do this without relying on technology transfer from the West.
For potential Indian entrepreneurs, Bharat Biotech is a strong example. An Indian biotech company with its own manufacturing assets and intellectual property can be more dependable than pure contract manufacturing. It can also deliver better margins than contract manufacturing. However, this requires patient and capital-disciplined promoters. They must be willing to endure a long development phase with zero revenue..
Related Article: 20 Profitable Biotechnology Manufacturing Business Ideas for Startups
How NPCS Supports Biotech Manufacturing Entrepreneurs
An entrepreneur’s decision to enter biotech manufacturing is often shaped by a preliminary feasibility study. It can either lead to success or become a costly mistake that leaves the business undercapitalized.
At Niir Project Consultancy Services (NPCS), we provide professional consultation for market surveys. We also prepare detailed techno-economic feasibility reports (DPRs) for starting a new enterprise or industry.
The feasibility study we prepare considers the manufacturing process in detail. It also includes an analysis of market demand and surveys. We prepare a process flow diagram as well. The study evaluates the product mix and production capacities. It identifies all required machinery and raw materials. It also includes a full assessment of project economics, including profitability.
Firstly, We provide data analysis to help entrepreneurs assess feasibility and profitability. We also study the future scalability of the proposed enterprise. This helps investors make decisions before committing capital. The analysis is based on realistic data, not on unrealistic projections.
In a biotech manufacturing venture, NPCS reports may include fermentation-based API plants, enzyme manufacturing units, bio-pesticide production, diagnostic kit assembly, and nutraceuticals on a contract manufacturing basis.
Furthermore, These reports provide promoters with essential technical specifications and details of regulatory processes.They also include financial projections needed to approach banks, investors, and government grant programs with a credible project report. Furthermore, For more information about our services(Biotechnology manufacturing opportunities in India)
Biotech Manufacturing Segment Overview: Key Parameters at a Glance
| Segment | Approx. Investment Range | Revenue Potential | Export Viability | Key Regulatory Body |
| Biosimilar API Manufacturing | ₹10 Cr – ₹50 Cr | ₹30 Cr – ₹200 Cr | High | CDSCO / USFDA / EMA |
| Industrial Enzyme Manufacturing | ₹3 Cr – ₹8 Cr | ₹10 Cr – ₹40 Cr | High | FSSAI / BIS |
| Bio-Pesticide & Biofertiliser | ₹1.5 Cr – ₹4 Cr | ₹5 Cr – ₹20 Cr | Medium | CIB&RC / State Agri Depts |
| Diagnostic Reagent & Kits | ₹2 Cr – ₹12 Cr | ₹8 Cr – ₹50 Cr | Medium–High | CDSCO |
| Probiotic & Nutraceutical CMO | ₹4 Cr – ₹10 Cr | ₹12 Cr – ₹60 Cr | Medium–High | FSSAI / AYUSH |
FAQs
Q1. Is biotechnology manufacturing profitable in India?
Yes, the manufacturing of biotechnological products is highly profitable. However, profit margins will vary from segment to segment. Areas like biosimilars, industrial enzymes, probiotics, and diagnostic products currently promise good margins. The level of profitability would depend upon the product, ability to attain and retain market access, and adherence to regulatory processes.(Biotechnology manufacturing opportunities in India)
Q2. What would be the capital investment needed for starting a biotech manufacturing unit?
The investment required would vary considerably depending on the segment. A basic biofertilizer unit can be started at around Rs 1.5 crore, while a fully-fledged biosimilar manufacturing unit may demand an investment of Rs 10 to 50 crore.
Q3. What kind of business venture within biotech manufacturing is suitable for MSMEs?
The most suitable biotech business ventures for MSMEs are manufacturing of industrial enzymes, biofertilizers and biopesticides, probiotics contract manufacturing etc.
Q4. What are the licenses needed to start a biotech manufacturing unit?
Depending upon the nature of the products being manufactured, the necessary approvals would be needed from various authorities such as CDSCO, FSSAI, CIB & RC, State Pollution Control Boards, local industrial bodies etc.
Q5. Can biotech startups be funded by the government?
Yes. There are a number of grants, seed loans, incubation centers, government programs such as BIRAC, DBT, Startup India, BioNEST, CGTMSE, state government schemes, etc that fund the biotech industry.
Q6. What are the risks involved in biotech manufacturing?
The major risks involved in a biotech manufacturing unit are; regulatory issues, failure to achieve technology scaling up, capital requirements, quality compliance failures, market risks etc.
Q7. Is the manufacturing of biotech products a good export business?
Yes, the manufacturing of biotechnology products like biosimilars, enzymes, diagnostics, biofertilizers and nutraceutical ingredients to various international destinations has already commenced by some Indian manufacturers. The trend will rise.
Q8. Which area is projected to grow fastest within biotech manufacturing by 2030 in India?
The fastest growing sectors in biotech manufacturing are predicted to be biosimilars, industrial biotechnology, precision diagnostics, probiotics, and fermentation-based products.(Biotechnology manufacturing opportunities in India)
